Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Medicenna Therapeutics Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MDNA
New York
8731
https://www.medicenna.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Medicenna Therapeutics Corp
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
- Nov 17th, 2023 12:00 pm
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
- Nov 14th, 2023 1:30 pm
MDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11
- Nov 13th, 2023 12:00 pm
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
- Nov 9th, 2023 1:56 pm
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Nov 6th, 2023 12:00 pm
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Nov 3rd, 2023 4:00 pm
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
- Oct 27th, 2023 11:55 am
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
- Oct 25th, 2023 11:00 am
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
- Oct 24th, 2023 11:15 am
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
- Oct 10th, 2023 11:07 am
Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy
- Oct 3rd, 2023 11:00 am
Medicenna Announces Results of Annual and Special Meeting of Shareholders
- Sep 28th, 2023 9:00 pm
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
- Sep 28th, 2023 11:00 am
Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?
- Sep 26th, 2023 2:15 pm
Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 11:00 am
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
- Aug 28th, 2023 11:00 am
MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…
- Aug 15th, 2023 4:20 pm
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
- Aug 14th, 2023 11:00 am
Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
- Aug 9th, 2023 11:30 am
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
- Aug 8th, 2023 11:00 am
Scroll